Clare Gilson
Royal Marsden NHS Foundation Trust(GB)Royal Marsden Hospital(GB)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Prostate Cancer Diagnosis and Treatment, Cancer, Lipids, and Metabolism, Hormonal and reproductive studies
Most-Cited Works
- → Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy(2017)1,740 cited
- → Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial(2018)1,235 cited
- → Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol(2018)246 cited
- → Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer(2019)201 cited
- → Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial(2022)115 cited
- → Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol(2023)90 cited
- → Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)(2022)73 cited
- → Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial(2017)70 cited
- → This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols(2019)59 cited
- → Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform(2016)57 cited